Abcore Revenue and Competitors
Estimated Revenue & Valuation
- Abcore's estimated annual revenue is currently $2.8M per year.
- Abcore's estimated revenue per employee is $155,000
Employee Data
- Abcore has 18 Employees.
- Abcore grew their employee count by -10% last year.
Abcore's People
Name | Title | Email/Phone |
---|---|---|
1 | Sr. VP Discovery Operations | Reveal Email/Phone |
2 | Accounting Manager | Reveal Email/Phone |
3 | Senior Laboratory Animal Technician | Reveal Email/Phone |
4 | Project Coordinator | Reveal Email/Phone |
5 | Marketing Assistant | Reveal Email/Phone |
6 | Research Associate | Reveal Email/Phone |
7 | Animal Technician | Reveal Email/Phone |
Abcore Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Abcore?
Founded in 2011 Abcore, Inc. is a privately held biotechnology company focused on generation of polyclonal, monoclonal, and recombinant antibodies and is the largest camelid facility in the United States. Abcore is a leader in antibody discovery using phage display and generating single domain antibodies. Abcore has worked with some of the largest pharmaceutical companies in the world on early stage drug development and antibody discovery. Abcore has built a robust antibody discovery platform which utilizes both naïve and immunized antibody libraries.
keywords:N/AN/A
Total Funding
18
Number of Employees
$2.8M
Revenue (est)
-10%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $5.3M | 39 | N/A | N/A |
#2 | $6.7M | 51 | -14% | N/A |
#3 | N/A | 93 | 7% | N/A |
#4 | $34.6M | 143 | 11% | N/A |